Scott H. Kollins

Scott H. Kollins


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2009 in JAMA
Verified
Journal Article
Open access
PDF file
NVNora D Volkow
Nora D Volkow
GWGene-Jack Wang
Gene-Jack Wang
SKScott H. Kollins
Scott H. Kollins
TWTim L. Wigal
Tim L. Wigal
JNJeffrey H. Newcorn
Jeffrey H. Newcorn
JSJames M. Swanson
James M. Swanson
Attention-deficit/hyperactivity disorder (ADHD) is characterized by symptoms of inattention, hyperactivity, or impulsivity that produce impairment across cognitive, behavioral, and interpersonal domains.1 Although for many years it was believed to be a disorder of childhood and adolescence, it is now recognized to also occur in adulthood. It is estimated that ADHD affects 3% to 5% of the US adult population,2 which makes it one of the most prevalent of all psychiatric disorders.

1 April 2020 in The Lancet Digital Health
Verified
Journal Article
Open access
SKScott H. Kollins
Scott H. Kollins
DDDenton J DeLoss
Denton J DeLoss
ECElena Cañadas
Elena Cañadas
JLJacqueline Lutz
Jacqueline Lutz
RFRobert L Findling
Robert L Findling
SFStephen V Faraone
Stephen V Faraone
Attention-deficit hyperactivity disorder (ADHD) is a common paediatric neurodevelopmental disorder with substantial effect on families and society. Alternatives to traditional care, including novel digital therapeutics, have shown promise to remediate cognitive deficits associated with this disorder and may address barriers to standard therapies, such as pharmacological interventions and behavioural therapy. AKL-T01 is an investigational digital therapeutic designed to target attention and cognitive control delivered through a video game-like interface via at-home play for 25 min per day, 5 days per week for 4 weeks. This study aimed to assess whether AKL-T01 improved attentional performance in paediatric patients with ADHD. The Software Treatment for Actively Reducing Severity of ADHD (STARS-ADHD) was a randomised, double-blind, parallel-group, controlled trial of paediatric patients (aged 8-12 years, without disorder-related medications) with confirmed ADHD and Test of Variables of Attention (TOVA) Attention Performance Index (API) scores of -1·8 and below done by 20 research institutions in the USA. Patients were randomly assigned 1:1 to AKL-T01 or a digital control intervention. The primary outcome was mean change in TOVA API from pre-intervention to post-intervention. Safety, tolerability, and compliance were also assessed. Analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02674633 and is completed. Between July 15, 2016, and Nov 30, 2017, 857 patients were evaluated and 348 were randomly assigned to receive AKL-T01 or control. Among patients who received AKL-T01 (n=180 [52%]; mean [SD] age, 9·7 [1·3] years) or control (n=168 [48%]; mean [SD] age, 9·6 [1·3] years), the non-parametric estimate of the population median change from baseline TOVA API was 0·88 (95% CI 0·24-1·49; p=0·0060). The mean (SD) change from baseline on the TOVA API was 0·93 (3·15) in the AKL-T01 group and 0·03 (3·16) in the control group. There were no serious adverse events or discontinuations. Treatment-related adverse events were mild and included frustration (5 [3%] of 180) and headache (3 [2%] of 180). Patient compliance was a mean of 83 (83%) of 100 expected sessions played (SD, 29·2 sessions). Although future research is needed for this digital intervention, this study provides evidence that AKL-T01 might be used to improve objectively measured inattention in paediatric patients with ADHD, while presenting minimal adverse events. Sponsored by Akili Interactive Labs.

21 September 2010 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
NVNora D Volkow
Nora D Volkow
GWG-J Wang
G-J Wang
JNJ H Newcorn
J H Newcorn
SKScott H. Kollins
Scott H. Kollins
TWT L Wigal
T L Wigal
JSJ M Swanson
J M Swanson
Attention-deficit hyperactivity disorder (ADHD) is typically characterized as a disorder of inattention and hyperactivity/impulsivity but there is increasing evidence of deficits in motivation. Using positron emission tomography (PET), we showed decreased function in the brain dopamine reward pathway in adults with ADHD, which, we hypothesized, could underlie the motivation deficits in this disorder. To evaluate this hypothesis, we performed secondary analyses to assess the correlation between the PET measures of dopamine D2/D3 receptor and dopamine transporter availability (obtained with [11C]raclopride and [11C]cocaine, respectively) in the dopamine reward pathway (midbrain and nucleus accumbens) and a surrogate measure of trait motivation (assessed using the Achievement scale on the Multidimensional Personality Questionnaire or MPQ) in 45 ADHD participants and 41 controls. The Achievement scale was lower in ADHD participants than in controls (11±5 vs 14±3, P<0.001) and was significantly correlated with D2/D3 receptors (accumbens: r=0.39, P<0.008; midbrain: r=0.41, P<0.005) and transporters (accumbens: r=0.35, P<0.02) in ADHD participants, but not in controls. ADHD participants also had lower values in the Constraint factor and higher values in the Negative Emotionality factor of the MPQ but did not differ in the Positive Emotionality factor—and none of these were correlated with the dopamine measures. In ADHD participants, scores in the Achievement scale were also negatively correlated with symptoms of inattention (CAARS A, E and SWAN I). These findings provide evidence that disruption of the dopamine reward pathway is associated with motivation deficits in ADHD adults, which may contribute to attention deficits and supports the use of therapeutic interventions to enhance motivation in ADHD.

1 November 2006 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
LGLaurence Greenhill
Laurence Greenhill
SKScott H. Kollins
Scott H. Kollins
HAHoward Abikoff
Howard Abikoff
JMJames Mccracken
James Mccracken
MRMark Riddle
Mark Riddle
TCTom Cooper
Tom Cooper

1 March 2001 in Journal of Applied Behavior Analysis
Verified
Journal Article
Closed access
TCThomas S. Critchfield
Thomas S. Critchfield
SKScott H. Kollins
Scott H. Kollins
Recent basic research on human temporal discounting is reviewed to illustrate procedures, summarize key findings, and draw parallels with both nonhuman animal research and conceptual writings on self‐control. Lessons derived from this research are then applied to the challenge of analyzing socially important behaviors such as drug abuse, eating and exercise, and impulsiveness associated with attention deficit hyperactivity disorder. Attending to the broader temporal context in which behavior occurs may aid in the analysis of socially important behavior. Applying this perspective to the study of behavior in natural environments also highlights the importance of combining methodological flexibility with conceptual rigor to promote the extension of applied behavior analysis to a broader array of socially important behaviors.

1 October 2005 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
SKScott H. Kollins
Scott H. Kollins
FMF. Joseph McClernon
F. Joseph McClernon
BBernard Fuemmeler
Bernard Fuemmeler
Research from JAMA Psychiatry — Association Between Smoking and Attention-Deficit/Hyperactivity Disorder Symptoms in a Population-Based Sample of Young Adults